Last reviewed · How we verify
TQB2868 injection — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
TQB2868 injection (TQB2868 injection) — Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. TQB2868 injection's mechanism is not publicly available.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TQB2868 injection TARGET | TQB2868 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TQB2868 injection CI watch — RSS
- TQB2868 injection CI watch — Atom
- TQB2868 injection CI watch — JSON
- TQB2868 injection alone — RSS
Cite this brief
Drug Landscape (2026). TQB2868 injection — Competitive Intelligence Brief. https://druglandscape.com/ci/tqb2868-injection. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing